|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Prepaid expense and other current assets | ||||||||||||||||||||
| Subscription receivable | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total right-of-use assets, net | ||||||||||||||||||||
| Intangible assets, net (provisional) | ||||||||||||||||||||
| Goodwill (provisional) | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| D&O insurance payable | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Accrued clinical site costs | ||||||||||||||||||||
| Convertible note payable and accrued interest | ||||||||||||||||||||
| Convertible note payable and accrued interest, current | ||||||||||||||||||||
| Insurance loan payable | ||||||||||||||||||||
| Warrant liabilities (Note 9) | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Lease liability, short term | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible note payable and accrued interest, long term | ||||||||||||||||||||
| Lease liability, noncurrent | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Nondesignated Preferred Stock | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 43,157,744 and 31,734,333 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit | ||||||||||||||||||||
Loading...
